Page last updated: 2024-08-26

nicotine and rivastigmine

nicotine has been researched along with rivastigmine in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Bellman, K; Knegtel, RM; Settimo, L1
Adam, BL; Gao, J; Terry, AV1
Caricati-Neto, A; D'angelo, LC; Garcia, AG; Hyppolito Jurkiewicz, N; Jurkiewicz, A; Reuter, H1
Bermudez, I; Groot-Kormelink, PJ; Smulders, CJ; van Kleef, RG; Vijverberg, HP; Zwart, R1
Arias, E; Gallego-Sandín, S; García, AG; López, MG; Villarroya, M1
Aasen, I; Kumari, V; Reed, C; Sharma, T1
Almkvist, O; Darreh-Shori, T; Kadir, A; Långström, B; Nordberg, A; Wall, A1
Balogh, R; Berkó, S; Budai-Szűcs, M; Csányi, E; Sinkó, B; Takács-Novák, K; Tóth, G; Vizserálek, G1
Bazan, R; Bazan, SG; Braga, GP; El Dib, R; Luvizutto, GJ; Resende, LA1

Reviews

1 review(s) available for nicotine and rivastigmine

ArticleYear
Pharmacological interventions for unilateral spatial neglect after stroke.
    The Cochrane database of systematic reviews, 2015, Nov-06, Issue:11

    Topics: Administration, Cutaneous; Humans; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Perceptual Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Stroke; Stroke Rehabilitation

2015

Trials

2 trial(s) available for nicotine and rivastigmine

ArticleYear
Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Schizophrenia research, 2006, Volume: 85, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotine; Phenylcarbamates; Physostigmine; Psychomotor Performance; Rivastigmine; Schizophrenia; Severity of Illness Index; Verbal Behavior

2006
Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Psychopharmacology, 2007, Volume: 191, Issue:4

    Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Carbon Radioisotopes; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Nicotine; Phenylcarbamates; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Nicotinic; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome

2007

Other Studies

9 other study(ies) available for nicotine and rivastigmine

ArticleYear
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
    Bioorganic & medicinal chemistry letters, 2014, Mar-15, Volume: 24, Issue:6

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; Neurons; Neuroprotective Agents; Nicotine; Peptide Fragments; Rats; Receptors, N-Methyl-D-Aspartate

2014
Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
    European journal of pharmacology, 2004, Oct-25, Volume: 503, Issue:1-3

    Topics: Acetylcholine; Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Donepezil; Drug Synergism; Electric Stimulation; Galantamine; In Vitro Techniques; Indans; Male; Muscle Contraction; Muscle, Smooth; Nicotine; Nicotinic Agonists; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Wistar; Receptors, Purinergic; Rivastigmine; Stimulation, Chemical; Synaptic Transmission; Tacrine; Vas Deferens

2004
Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
    European journal of pharmacology, 2005, Feb-21, Volume: 509, Issue:2-3

    Topics: Acetylcholine; Alkaloids; Animals; Atropine; Azocines; Binding, Competitive; Cholinergic Agents; Cholinesterase Inhibitors; Dichlorvos; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Membrane Potentials; Models, Biological; Nicotine; Oocytes; Phenylcarbamates; Physostigmine; Plasmids; Quinolizines; Receptors, Nicotinic; Rivastigmine; Scopolamine; Tacrine; Xenopus laevis

2005
Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 315, Issue:3

    Topics: Aconitine; Amyloid beta-Peptides; Apoptosis; Benzopyrans; Cell Culture Techniques; Cell Line, Tumor; Cholinesterase Inhibitors; Chromones; Donepezil; Dose-Response Relationship, Drug; Enzyme Inhibitors; Galantamine; Humans; Indans; L-Lactate Dehydrogenase; Morpholines; Neuroblastoma; Neuroprotective Agents; Nicotine; Nitriles; Okadaic Acid; Phenylcarbamates; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Nicotinic; Rivastigmine

2005
Permeability test for transdermal and local therapeutic patches using Skin PAMPA method.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Aug-30, Volume: 76

    Topics: Administration, Cutaneous; Chemistry, Pharmaceutical; Fentanyl; Humans; In Vitro Techniques; Ketoprofen; Kinetics; Membranes, Artificial; Models, Biological; Nicotine; Permeability; Rivastigmine; Skin; Skin Absorption; Solubility; Technology, Pharmaceutical; Transdermal Patch

2015